判断标准不是单次服务成本，而是这项能力是否触及价值导向合同下的归属人头，拥有它是否能提高每位提供者的贡献。 医疗服务提供商面临的问题版本并不通用。38,000人头的 downside risk 已承担，却缺少定价所需的分次成本数据——忽略分次成本的答案必然出错。分析必须从 payer mix 和 panel size 出发，而非从收入出发。
判断标准不是单次服务成本，而是这项能力是否触及价值导向合同下的归属人头，拥有它是否能提高每位提供者的贡献。 医疗服务提供商面临的问题版本并不通用。38,000人头的 downside risk 已承担，却缺少定价所需的分次成本数据——忽略分次成本的答案必然出错。分析必须从 payer mix 和 panel size 出发，而非从收入出发。
聘用与外包通常按分次成本争论，而这其实是最不关键的输入。外包功能在 panel size 低时通常更便宜，高时则更贵，因此诚实的比较取决于你本就必须预测的归属人头。
决定性问题是与价值导向合同的接近程度。触及这些合同下患者就医体验、或能积累知识以改善 payer mix 的能力，即使溢价也值得拥有。其余都是采购决策。
第三个因素是波动性。拥有功能能控制38,000归属人头的质量与时效；外包则换来灵活性。哪种更重要，取决于合同是否惩罚分次成本的波动。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 讨论完全围绕分次成本展开
✓ 拟聘用岗位的 panel size 被假设，而非从归属人头估算得出
✓ 该功能触及价值导向合同下的人头就医体验
通常会让情况更糟的做法。 把能积累管理价值导向合同下归属人头知识的功能外包出去——它每年成本更低，却也越来越弱。
It is for you if you run or finance a healthcare provider and the debate is being conducted entirely on hourly rates. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗服务提供商. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Quick Market Scan · sample company profile
The move. Turn $6.8 M downside-risk liability into a $22–35 M licensing platform within 36 months.
The leak it closes. Eliminates $6.8 M downside exposure by enabling proactive utilization management.
The assumption it rests on. Cost-measurement platform achieves <5 % variance versus manual abstraction within 12 months — the engine put the probability at 0.75.
| Investment required | $2.1–3.5 M over 36 months |
| Expected return | 6.3–16.7× cash-on-cash within 36 months based on $196 M current revenue base. |
| Revenue, year 1 | $0 licensing revenue; $1.8 M internal cost avoidance |
| Revenue, year 2 | $4.2 M licensing ARR (40 physicians × $120K + 5 external practices × $400K) |
| Revenue, year 3 | $13.5 M licensing ARR (90 physicians × $120K + 18 external practices × $400K) plus $4–8 M shared-savings upside |
| Exit criteria | Terminate platform investment if variance exceeds 8 % by Month 18 OR if fewer than 40 physicians sign licensing agreements by Month 24; redeploy remaining capital to ASC surgeon-retention track. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Organizational Alignment Model, one of 29 engagements the platform runs. For 医疗服务提供商 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
在 fully loaded 内部成本低于同等产出外部费率时的利用率。明确算出这个盈亏平衡点——它通常比人们以为的低，讨论到此为止。
积累的知识构成你所售内容的部分。失去它不是成本项，而是你能收取的价格缓慢下降。
看波动而非平均值。外包工作平均值常可比，但分布更宽，这与客户是否注意到同样重要。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית